openPR Logo
Press release

Pancreatic Ductal Adenocarcinoma Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therap

04-10-2025 06:27 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Pancreatic Ductal Adenocarcinoma Pipeline Analysis 2025 by DelveInsight

Pancreatic Ductal Adenocarcinoma Pipeline Analysis 2025 by DelveInsight

Pancreatic Ductal Adenocarcinoma Pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analyzes DelveInsight.

Pancreatic Ductal Adenocarcinoma Overview:

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a 5-year survival rate of under 10%. Most patients are diagnosed when the disease is already advanced, locally unresectable, or metastatic. The poor prognosis of PDAC is largely due to its complex, multifactorial nature. Early detection is challenging because symptoms typically do not manifest until the cancer has progressed and spread to other areas. Treatment of pancreatic cancer is hindered by both genetic and cellular factors. The significant mutational alterations in pancreatic tumors lead to gene instability, which plays a crucial role in the tumor's growth and its resistance to therapies.

Download our report @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Therapeutics Market.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
On March 26, 2025, the FDA approved cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors, based on data from the phase 3 CABINET study.
On December 4, 2024, the FDA approved zenocutuzumab for patients with NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma.
In June 2024, the FDA granted fast track designation to IBI343 for the treatment of advanced or metastatic PDAC.
Key Pancreatic Ductal Adenocarcinoma companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others are evaluating new drugs for Pancreatic Ductal Adenocarcinoma to improve the treatment landscape.
Promising Pancreatic Ductal Adenocarcinoma pipeline therapies in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis
The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.

Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:

Stage of development

Pancreatic Ductal Adenocarcinoma Route of administration

Target receptor

Monotherapy vs. combination therapy

Pancreatic Ductal Adenocarcinoma Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Pancreatic Ductal Adenocarcinoma Licensing agreements

Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pancreatic Ductal Adenocarcinoma Emerging Drugs

Onvansertib: Cardiff Oncology
Nadunolimab: Cantargia
Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Companies

There are over 80 major companies working on therapies for Pancreatic Ductal Adenocarcinoma. Among them, XOMA is one of the companies with drug candidates for this condition in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 140+ products under different phases of Pancreatic Ductal Adenocarcinoma clinical trials like

Pancreatic Ductal Adenocarcinoma Late stage Therapies (Phase III)
Pancreatic Ductal Adenocarcinoma Mid-stage Therapies (Phase II)
Pancreatic Ductal Adenocarcinoma Early-stage Therapies (Phase I)
Pancreatic Ductal Adenocarcinoma Pre-clinical and Pancreatic Ductal Adenocarcinoma Discovery stage Therapies
Pancreatic Ductal Adenocarcinoma Discontinued & Inactive Therapies

Pancreatic Ductal Adenocarcinoma pipeline report provides the Pancreatic Ductal Adenocarcinoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Ductal Adenocarcinoma Therapies and Key Pancreatic Ductal Adenocarcinoma Companies: Pancreatic Ductal Adenocarcinoma Clinical Trials and recent advancements https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment
• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type

Download Pancreatic Ductal Adenocarcinoma Sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ Pancreatic Ductal Adenocarcinoma Therapeutic Assessment https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns
4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)
7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Ductal Adenocarcinoma Discontinued Products
13. Pancreatic Ductal Adenocarcinoma Product Profiles
14. Pancreatic Ductal Adenocarcinoma Key Companies
15. Pancreatic Ductal Adenocarcinoma Key Products
16. Dormant and Discontinued Products
17. Pancreatic Ductal Adenocarcinoma Unmet Needs
18. Pancreatic Ductal Adenocarcinoma Future Perspectives
19. Pancreatic Ductal Adenocarcinoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Pancreatic Ductal Adenocarcinoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Ductal Adenocarcinoma Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therap here

News-ID: 3965937 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Pancreatic

Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025? The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate? There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025 Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025 Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025 Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Pancreatic Market to Insight By 2025: Top Key Vendors Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to